This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
HPV is transmitted through intimate contact regardless of travel destination. Vaccination before exposure is the most effective prevention.
Most common sexually transmitted infection worldwide; high-risk HPV types cause cervical, oropharyngeal, anal, and genital cancers. Preventable by vaccination.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Genital ulcer | 10% | Mild | Late |
| Itching | 5% | Mild | Late |
| Swollen lymph nodes | 3% | Mild | Late |
Human papillomavirus (HPV) infection is the most common sexually transmitted infection worldwide, caused by a group of non-enveloped, double-stranded DNA viruses belonging to the family Papillomaviridae. Over 200 HPV types have been identified, of which approximately 40 infect the anogenital epithelium and 14 are classified as high-risk oncogenic types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).
HPV is transmitted through direct skin-to-skin or mucosa-to-mucosa contact, predominantly during sexual activity (vaginal, anal, and oral intercourse). Vertical transmission from mother to neonate can occur during passage through an infected birth canal, potentially causing juvenile-onset recurrent respiratory papillomatosis. Non-sexual transmission through fomites is theoretically possible but epidemiologically negligible.
HPV types are broadly classified by oncogenic potential. High-risk types, particularly HPV 16 and HPV 18, are responsible for approximately 70% of cervical cancers and a substantial proportion of other anogenital and oropharyngeal malignancies. Low-risk types, principally HPV 6 and HPV 11, cause approximately 90% of genital warts (condylomata acuminata) and most cases of recurrent respiratory papillomatosis.
The global burden of HPV-related disease is enormous. An estimated 80% of sexually active individuals will acquire at least one HPV type during their lifetime. While the vast majority of infections are transient and asymptomatic, persistent infection with high-risk types can lead to malignant transformation over a period of 10–20 years, making HPV a critical target for cancer prevention strategies.
HPV infection represents a unique paradigm in infectious disease: the vast majority of infections are asymptomatic and self-resolving, yet persistent infection with high-risk types is the necessary cause of cervical cancer and a major contributor to several other malignancies. This dual nature — benign in most individuals but oncogenic in a minority — underlies the public health imperative for universal vaccination.
Approximately 90% of HPV infections are cleared by the host immune system within 2 years without any clinical consequence. The remaining 10% of infections that persist, particularly with HPV 16 and 18, carry significant risk of progression through precancerous lesions (cervical intraepithelial neoplasia, CIN) to invasive cancer. This progression typically spans 10–20 years, providing a substantial window for screening and intervention.
HPV-attributable cancers account for approximately 5% of all cancers worldwide. The WHO reported 604,000 new cervical cancer cases and 342,000 deaths in 2020, with the highest burden in sub-Saharan Africa, South-East Asia, and Central/South America. Beyond cervical cancer, HPV causes an estimated 88% of anal cancers, 70% of oropharyngeal cancers, 50% of penile cancers, and the majority of vulvar and vaginal cancers.
The introduction of prophylactic HPV vaccines represents one of the most significant advances in cancer prevention. The 9-valent vaccine (Gardasil 9) targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, offering protection against approximately 90% of cervical cancers and 90% of genital warts. The WHO has set a global target to eliminate cervical cancer as a public health problem (incidence <4/100,000) through 90% vaccination coverage, 70% screening coverage, and 90% treatment access by 2030.
While HPV infection itself does not typically cause acute emergencies, several presentations warrant urgent medical evaluation as they may indicate advanced HPV-related disease or complications:
Seek immediate medical attention for:
Heavy or uncontrollable vaginal bleeding (especially if postmenopausal or not associated with menstruation)
Rapidly growing anogenital lesions, particularly if ulcerated, fixed to underlying tissue, or causing significant pain
Sudden onset of urinary retention or inability to void
Lower limb edema with pelvic pain (suggesting lymphatic obstruction from advanced malignancy)
Unexplained weight loss combined with pelvic or rectal pain
Respiratory distress in an infant or young child with known recurrent respiratory papillomatosis (laryngeal obstruction)
Seek prompt (non-emergency) evaluation for:
New abnormal vaginal bleeding (intermenstrual, postcoital, or postmenopausal)
Persistent watery, blood-tinged, or malodorous vaginal discharge
Palpable neck mass (possible HPV-related oropharyngeal carcinoma)
Persistent sore throat, voice changes, or dysphagia lasting >3 weeks
Anal bleeding or persistent perianal lesions, particularly in immunocompromised individuals
Genital warts that are extensive, rapidly growing, or unresponsive to treatment
It is important to emphasize that routine screening (Pap smear, HPV DNA testing) is the primary mechanism for detecting precancerous changes before they progress to invasive disease. Women aged 25–65 should undergo regular cervical screening according to national guidelines.
Most common signs and symptoms
The clinical manifestations of HPV infection are highly variable, ranging from entirely asymptomatic carriage (the most common presentation) to visible warts and, in cases of persistent high-risk infection, precancerous and cancerous lesions.
Asymptomatic infection accounts for the majority of HPV cases. Most individuals never develop any visible signs or symptoms, and the infection is detected only through screening tests (HPV DNA testing, Pap smear) or seroconversion. This silent nature of HPV facilitates its continued transmission within the population.
Genital warts (condylomata acuminata), caused predominantly by HPV types 6 and 11, present as flesh-colored, soft, papillomatous growths in the anogenital region. They may be flat, papular, or pedunculated, and can be single or multiple (often in clusters described as "cauliflower-like"). Warts may be asymptomatic or cause pruritus, burning, or discomfort. In women, they commonly appear on the vulva, vaginal wall, and cervix; in men, on the penile shaft, glans, scrotum, and perianal area. Warts typically appear 2–3 months (range: 3 weeks to 8 months) after exposure.
Precancerous lesions of the cervix (CIN 1–3), vulva (VIN), vagina (VaIN), anus (AIN), and penis (PeIN) are generally asymptomatic and detected through screening. High-grade lesions (CIN 2/3) may occasionally cause abnormal vaginal bleeding, particularly postcoital. Invasive cervical cancer presents with irregular or postcoital vaginal bleeding, watery or blood-tinged vaginal discharge, pelvic pain, and in advanced stages, symptoms of ureteral obstruction, rectal involvement, or distant metastasis.
Oropharyngeal HPV infection is typically asymptomatic during initial infection. HPV-positive oropharyngeal squamous cell carcinoma may present with a painless neck mass, sore throat, dysphagia, or otalgia, and is increasingly common in younger, non-smoking populations.
Knowing the symptoms is the first step to a quick response.
HPV infection follows a chronic persistent infection model rather than the acute illness course seen in most infectious diseases. The timeline from initial infection to potential malignancy spans years to decades, with multiple possible outcomes at each stage.
Initial infection (weeks to months): Following inoculation of basal epithelial cells through microabrasions during skin-to-skin contact, HPV establishes infection by expressing early genes (E1, E2) that maintain the viral genome as a low-copy episome. During this phase, the infection is clinically and subclinically undetectable. The immune system is effectively evaded, as HPV does not cause viremia or cell lysis and actively downregulates innate immune signaling.
Productive infection (months 2–24): As infected basal cells differentiate and migrate toward the epithelial surface, viral gene expression increases, culminating in late gene expression (L1, L2 capsid proteins) and virion assembly in superficial cells. This phase may be clinically silent or manifest as genital warts (low-risk types) or low-grade squamous intraepithelial lesions (LSIL/CIN 1). Most infections (approximately 90%) are cleared by cell-mediated immune responses during this phase.
Persistent infection (years 2–10+): In a minority of individuals, the virus evades immune clearance and establishes persistent infection. This is the critical risk factor for malignant progression. During persistent infection, integration of HPV DNA into the host genome may occur, disrupting the E2 gene and leading to uncontrolled expression of E6 and E7 oncoproteins, which inactivate the p53 and Rb tumor suppressor pathways, respectively.
Precancerous progression (years 5–20): Persistent high-risk HPV infection drives progressive genomic instability and cellular dysplasia: CIN 1 → CIN 2 → CIN 3/carcinoma in situ. This progression is not inevitable and can halt or regress at any stage, but the probability of regression decreases with higher grade lesions.
Invasive cancer (years 10–30): If untreated, a proportion of high-grade lesions breach the basement membrane, establishing invasive carcinoma. The median time from initial HPV infection to invasive cervical cancer is approximately 15–20 years in immunocompetent women, but may be accelerated in HIV-positive individuals to as few as 5–10 years.
How this disease is identified
Diagnosis of HPV infection and its clinical sequelae employs a range of methods, from visual inspection to advanced molecular testing. The approach differs depending on whether the goal is to detect the virus itself, identify precancerous changes, or diagnose invasive disease.
HPV DNA testing is the most sensitive method for detecting HPV infection. PCR-based assays (e.g., Roche cobas HPV Test, Abbott RealTime HR HPV) detect high-risk HPV types with >95% sensitivity for CIN 2+ lesions. HPV DNA testing is approved as a primary cervical screening method in many countries, either alone or in co-testing with cytology. Newer HPV mRNA tests (e.g., Aptima HPV) detect E6/E7 oncogene transcripts, offering improved specificity for clinically significant infections.
Cervical cytology (Pap smear) remains a cornerstone of cervical cancer screening. Conventional or liquid-based cytology detects cellular abnormalities classified using the Bethesda System: ASC-US, LSIL, HSIL, ASC-H, AGC, and malignant cells. Sensitivity for CIN 2+ is approximately 50–70% per single test (improving with repeat testing), with specificity of 90–95%.
Visual inspection with acetic acid (VIA) is a low-cost screening method used extensively in low-resource settings. Application of 3–5% acetic acid causes acetowhite changes in areas of dysplasia. Sensitivity for CIN 2+ is approximately 70–80%, with lower specificity (65–85%). VIA enables a screen-and-treat approach in single-visit protocols.
Colposcopy with directed biopsy is the standard for histological confirmation of abnormal screening results. Colposcopy involves magnified visual examination of the cervix after acetic acid and Lugol iodine application, with targeted biopsies of suspicious areas. Histopathology of biopsy specimens provides definitive grading (CIN 1, 2, or 3) and is the reference standard against which all screening methods are evaluated.
Genital warts are typically diagnosed by visual inspection alone. Biopsy is indicated only when the diagnosis is uncertain, lesions are atypical, the patient is immunocompromised, or lesions fail to respond to standard treatment.
Available treatment methods
There is no antiviral therapy that directly eliminates HPV. Treatment is directed at managing the clinical manifestations of infection — visible warts, precancerous lesions, and invasive cancers. The immune system clears most infections naturally, and treatment decisions are guided by the type, location, and severity of lesions.
Treatment of genital warts:
Patient-applied therapies: Imiquimod 5% cream (immune response modifier, applied 3 times/week for up to 16 weeks), podophyllotoxin 0.5% solution or gel (applied twice daily for 3 days, then 4 days off, up to 4 cycles), sinecatechins 15% ointment (applied 3 times daily for up to 16 weeks)
Provider-administered therapies: Cryotherapy with liquid nitrogen (most widely used, 1–3 sessions), trichloroacetic acid (TCA) 80–90% application, electrocautery, surgical excision, and laser ablation (CO₂ laser for extensive or recalcitrant warts)
Recurrence rates are 20–30% regardless of treatment modality, reflecting the inability of local treatments to eradicate latent virus in surrounding tissue
Treatment of cervical precancerous lesions:
CIN 1: Observation (60–80% spontaneous regression within 2 years); treatment only if persistent >2 years
CIN 2/3: Excisional treatment is standard, including loop electrosurgical excision procedure (LEEP), cold knife conization, or laser conization. Ablative methods (cryotherapy, thermal ablation) are alternatives in low-resource settings. Cure rates exceed 90% with adequate excision margins
Adenocarcinoma in situ (AIS): Cold knife conization with negative margins; hysterectomy if fertility is not desired
Treatment of invasive HPV-related cancers follows standard oncological protocols including surgery, radiation therapy, chemotherapy (cisplatin-based), and targeted therapies (bevacizumab for advanced cervical cancer). Immunotherapy with checkpoint inhibitors (pembrolizumab) is approved for recurrent or metastatic cervical cancer with PD-L1 expression.
Most cases are effectively treated with early diagnosis.
How to protect yourself
HPV prevention is built on three complementary pillars: vaccination, screening, and treatment — the WHO's integrated strategy for cervical cancer elimination.
HPV vaccination is the most effective primary prevention measure. Three vaccines are or have been licensed globally:
9-valent (Gardasil 9): Targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58. Protects against approximately 90% of cervical cancers, 90% of genital warts, and a high proportion of other HPV-related cancers. This is currently the most widely recommended formulation.
Quadrivalent (Gardasil): Targets HPV types 6, 11, 16, 18.
Bivalent (Cervarix): Targets HPV types 16, 18, with significant cross-protection against related types.
The WHO recommends HPV vaccination for girls aged 9–14 years as the primary target, before sexual debut. A single-dose schedule was endorsed by the WHO in 2022 based on evidence of non-inferior immunogenicity, simplifying implementation. Two-dose schedules (0, 6–12 months) remain standard in many countries for ages 9–14, with three doses for those ≥15 years or immunocompromised individuals. Vaccine efficacy against persistent HPV 16/18 infection exceeds 95% in HPV-naive individuals.
Cervical screening serves as secondary prevention to detect precancerous lesions. The WHO recommends HPV DNA testing as the preferred screening method, starting at age 30 (or 25 in high-burden settings), every 5–10 years. Screen-and-treat approaches are recommended for low-resource settings.
Barrier methods (male and female condoms) provide partial protection against HPV, reducing transmission by approximately 70%. However, since HPV can infect areas not covered by condoms, they do not eliminate risk. Male circumcision reduces HPV acquisition in males by approximately 30% and reduces cervical cancer risk in female partners.
Behavioral measures include limiting the number of sexual partners and avoiding tobacco use, which impairs local cervical immunity and increases the risk of HPV persistence and progression.
Preparation is the best protection.
HPV infection is globally ubiquitous and is not classified as a travel-specific disease. However, several travel-related considerations are relevant to HPV prevention and management:
Pre-travel HPV vaccination: Travelers, particularly young adults who may not have been vaccinated in childhood, should ensure they have completed the HPV vaccine series before extended travel. The 9-valent HPV vaccine is recommended for all individuals through age 26, and shared clinical decision-making for ages 27–45 may be appropriate for those at risk. Travelers to regions with high cervical cancer incidence (sub-Saharan Africa, South-East Asia, Latin America) should be particularly aware of the global HPV burden.
Sexual health during travel: International travelers may engage in sexual activity with new partners during their journey. Studies demonstrate that travelers have higher rates of casual sexual encounters and may be less consistent with barrier method use. Travelers should carry and use condoms, though condoms provide only partial protection against HPV due to skin-to-skin transmission in uncovered areas.
Screening continuity: Long-term travelers and expatriates should maintain their cervical screening schedule. Women living abroad for extended periods should identify local healthcare facilities capable of performing Pap smears or HPV testing. In many lower-income countries, screening availability may be limited to urban centers.
Access to HPV-related healthcare abroad: Travelers with known HPV-related conditions (ongoing treatment for genital warts, surveillance after CIN treatment) should bring relevant medical records and ensure continuity of care. Some HPV treatments (imiquimod, podophyllotoxin) may not be available in all countries.
There are no entry requirements related to HPV status for any country, and HPV infection is not subject to quarantine or notification requirements for international travel.
Statistics and geographic data
HPV infection is the most prevalent sexually transmitted infection globally, with an estimated point prevalence of 11.7% among women worldwide (approximately 291 million women with cervical HPV infection at any given time). Prevalence peaks in young women under 25 years (20–25%) and shows a second, smaller peak in some populations around age 45–55.
Global cervical cancer burden (WHO 2020 data): An estimated 604,000 new cases and 342,000 deaths annually. Cervical cancer is the fourth most common cancer in women globally but the leading cause of cancer death in 36 countries, predominantly in sub-Saharan Africa and South-East Asia. The highest incidence rates are observed in Eswatini (75/100,000), Malawi (67/100,000), and Zambia (65/100,000), compared to <10/100,000 in most high-income countries with established screening programs.
Other HPV-attributable cancers: Beyond cervical cancer, HPV causes an estimated 45,000 oropharyngeal cancers (predominantly in men in high-income countries, incidence rising sharply), 35,000 anal cancers, 13,000 penile cancers, 8,500 vulvar cancers, and 12,000 vaginal cancers annually worldwide. HPV-positive oropharyngeal cancer incidence has increased by 300–400% in several Western countries since the 1980s, now exceeding cervical cancer incidence in the US.
HPV type distribution: In cervical cancers globally, HPV 16 accounts for approximately 55% and HPV 18 for approximately 15% of cases. The additional types covered by the 9-valent vaccine (31, 33, 45, 52, 58) account for another 15–20%. Type distribution varies geographically: HPV 16 predominance is consistent worldwide, but the relative contribution of other types differs by region.
Impact of vaccination programs: Countries with early vaccine adoption (Australia, UK, Denmark, Sweden) have demonstrated dramatic reductions in HPV infection prevalence (up to 90% in vaccinated cohorts), genital warts (up to 90% reduction), and high-grade cervical abnormalities (up to 87% reduction in CIN 3). Australia is projected to achieve cervical cancer elimination by the mid-2030s, becoming the first country to do so.
Who is most at risk
Risk factors for HPV infection and progression to HPV-related disease are well characterized through decades of epidemiological research.
Risk factors for HPV acquisition:
Number of sexual partners: The strongest predictor of HPV infection. Lifetime risk exceeds 80% in sexually active individuals with ≥2 partners
Age at sexual debut: Earlier onset of sexual activity increases cumulative exposure time
New sexual partner: Acquisition risk is highest in the first 6 months of a new sexual relationship
Male partner's sexual history: A woman's HPV risk correlates with her male partner's number of prior partners
Lack of HPV vaccination: Unvaccinated individuals remain susceptible to vaccine-type infections
Inconsistent condom use: Though condoms are partially protective (~70% risk reduction), they do not eliminate transmission
Risk factors for HPV persistence and progression to cancer:
HPV type: HPV 16 is more likely to persist and progress than any other type; HPV 16 and 18 together account for 70% of cervical cancers
Immunosuppression: HIV-positive women have 6-fold increased risk of cervical cancer; organ transplant recipients have similarly elevated risk. CD4 count <200 dramatically increases persistence and progression
Tobacco smoking: Active smoking increases cervical cancer risk by 2–3-fold, mediated by carcinogenic metabolites concentrated in cervical mucus and impaired local immune function
High parity: ≥5 full-term pregnancies increases cervical cancer risk, possibly through hormonal and traumatic effects on the cervical epithelium
Long-term oral contraceptive use: ≥5 years of combined oral contraceptive use modestly increases cervical cancer risk (relative risk 1.3–1.9), though the effect diminishes after cessation
Co-infection with other STIs: Chlamydia trachomatis and herpes simplex virus type 2 co-infection may increase HPV persistence
Nutritional deficiencies: Low folate, vitamin C, and carotenoid levels have been associated with increased progression risk
The interplay of these factors creates a spectrum of individual risk that informs screening frequency and clinical management decisions.
Potential complications
The complications of HPV infection are primarily oncological, developing over years to decades in a subset of individuals with persistent high-risk infections. HPV is directly responsible for an estimated 5% of all human cancers worldwide.
Cervical cancer is the most well-established HPV complication. Virtually 99.7% of cervical cancers contain HPV DNA, making it the first human cancer demonstrated to be caused by an infectious agent. The two major histological types are squamous cell carcinoma (70–80%) and adenocarcinoma (20–25%), both driven by persistent HPV infection but with adenocarcinoma less efficiently detected by cytological screening. Advanced cervical cancer can cause ureteral obstruction leading to renal failure, rectovaginal fistula, lymphedema, and distant metastases.
Anogenital cancers beyond the cervix represent a growing public health concern. Anal cancer (88% HPV-attributable) has increased in incidence by 2–3% annually in high-income countries, with particularly elevated rates among men who have sex with men (MSM), especially those co-infected with HIV (incidence of 75–130/100,000 in HIV-positive MSM). Vulvar and vaginal cancers are HPV-positive in approximately 70% and 75% of cases, respectively. Penile cancer (50% HPV-attributable) is rare in high-income countries but represents a significant burden in parts of Africa, South America, and Asia.
Oropharyngeal cancer caused by HPV (predominantly HPV 16) is now the most rapidly increasing HPV-related malignancy in high-income countries. In the United States, HPV-positive oropharyngeal cancer has surpassed cervical cancer in incidence. Risk factors include a high number of oral sexual partners and are more common in men (male-to-female ratio approximately 4:1).
Recurrent respiratory papillomatosis (RRP) is a rare but debilitating complication, predominantly caused by HPV types 6 and 11. Juvenile-onset RRP (acquired perinatally) causes recurrent papillomatous growths in the larynx and tracheobronchial tree, requiring multiple surgical interventions (average 4–5/year) and potentially leading to airway obstruction. Malignant transformation to squamous cell carcinoma occurs in approximately 2–5% of cases.
Psychosocial complications of HPV infection, including anxiety, depression, sexual dysfunction, and stigma, are significant but often underrecognized. Studies consistently demonstrate that HPV diagnosis negatively impacts quality of life and intimate relationships.
Expected outcomes and recovery
The prognosis of HPV infection is overwhelmingly favorable for the vast majority of infected individuals. Approximately 90% of infections are cleared spontaneously by cell-mediated immunity within 1–2 years, with no long-term clinical consequences. Among immunocompetent individuals under 30 years, median time to clearance is approximately 8 months for non-oncogenic types and 12–18 months for oncogenic types.
Genital warts carry an excellent prognosis for health but can significantly impact quality of life and psychological well-being. While treatment is effective in removing visible lesions, recurrence rates of 20–30% are common within the first 3 months. Most warts eventually resolve spontaneously, even without treatment, within 1–2 years. Genital warts caused by low-risk HPV types (6, 11) do not progress to cancer.
Cervical precancerous lesions have a variable natural history. CIN 1 regresses spontaneously in 60–80% of cases, while CIN 2 regresses in approximately 40% and CIN 3 in about 33%. However, untreated CIN 3 progresses to invasive carcinoma in approximately 30–50% of cases over 20–30 years. When detected and treated at the precancerous stage, cure rates exceed 90% with minimal long-term morbidity.
Invasive cervical cancer prognosis is stage-dependent. FIGO stage I disease (confined to cervix) has a 5-year survival rate of 80–93%, while stage IV disease (distant metastasis) has a 5-year survival of only 15–20%. Overall, the global 5-year survival for cervical cancer is approximately 60%, but ranges from >70% in high-income countries to <30% in some low-income settings, reflecting disparities in screening and treatment access.
HPV-positive oropharyngeal cancer has a notably better prognosis than HPV-negative disease, with 3-year overall survival rates of 82–87% compared to 55–60% for HPV-negative oropharyngeal cancers.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.